The company’s Bengaluru facility will be the first in India to be equipped with Agilent’s state-of-the-art RapidFire
Jubilant Biosys announced the addition of Agilent Technologies’ RapidFire/ MS screening technology to its integrated drug discovery platform.
RapidFire is a robust solid phase extraction technology that enables fast label-free detection of native compounds by mass spectrometry in a wide range of in vitro assays, DMPK/ ADME studies, hit/ lead applications for drug discovery across a broad spectrum of therapeutic areas and also for screening difficult targets that are not amenable to labelled assays. Jubilant Biosys’s Bengaluru facility will be the first in India to be equipped with Agilent’s state-of-the-art RapidFire.
“The installation of the Agilent RapidFire platform shows Jubilant’s continued commitment to make the necessary investments with an objective to remain on the cutting edge of drug discovery. This platform will enable us to increase our productivity and to enhance our capabilities to successfully meet the needs of our clients,” said Steven Hutchins, President, Jubilant Biosys (Drug Discovery Solutions).
“Agilent RapidFire solution enables our clients with increased accuracy, provides faster results, better economic value, enhanced analysis capabilities, improved efficiency while maintaining robustness and we are pleased to see Jubilant Biosys being the first organisation in India to take advantage of this cutting-edge technology,” said Bharat Bhardwaj, Country Manager, Agilent Technologies.
EP News Bureau